Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients

J Neurol. 2011 Mar;258(3):464-70. doi: 10.1007/s00415-010-5780-4. Epub 2010 Oct 17.

Abstract

Neuromyelitis optica (NMO) is an inflammatory/demyelinating disorder predominantly affecting the optic nerves and spinal cord. Recent findings showed an underlying humoral abnormality in NMO, characterized by a serum antibody against aquaporin-4 (Aqp-4-Ab). In this study, we evaluated the Aqp-4-Ab status among Turkish patients with NMO to determine the clinical and prognostic relevance. Serum samples from 35 consecutive patients with NMO followed at a single center and diagnosed according to the 2006 revised criteria, were evaluated for Aqp-4-Ab. All samples were obtained during a relapse prior to any immunosuppressive treatment. Aqp-4-Ab was positive in 21/35 (60%) patients. Among these cases, 11 had an EDSS of 6.0 or more, whereas only two patients in the seronegative group had such severe disability (p < 0.05). Overall, seropositive cases had a mean EDSS score of 5.1 ± 2.2 compared with 3.5 ± 1.7 in seronegative cases (p < 0.01). There were trends towards female predominance in seropositive cases and a monophasic course predominance in seronegative cases. Disease duration, age at onset, number of attacks and time to definite NMO did not differ between groups. Our findings in this single-center cohort suggest that the presence of Aqp-4-Ab might have a prognostic significance indicating a more severe disease course.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aquaporin 4 / blood*
  • Autoantibodies / biosynthesis
  • Autoantibodies / blood*
  • Biomarkers / blood
  • Child
  • Female
  • Follow-Up Studies
  • Humans
  • Magnetic Resonance Imaging / methods
  • Male
  • Middle Aged
  • Neuromyelitis Optica / blood*
  • Neuromyelitis Optica / diagnosis*
  • Neuromyelitis Optica / epidemiology
  • Prognosis
  • Turkey / epidemiology
  • Young Adult

Substances

  • Aquaporin 4
  • Autoantibodies
  • Biomarkers